Indian Covid-19 vaccine maker says recruitment for trials on track
The maker of one of India's leading Covid-19 vaccine candidates said on Tuesday its recruitment of volunteers for a late-stage trial of the shot was on track, after reports of a shortage of participants.
Bharat Biotech has signed up 13,000 volunteers for the Phase 3 trial, backed by India's government medical research body, and is progressing towards its goal of 26,000, the company said. The trial began in mid-November at multiple sites across India.
Local news reports last week suggested that some of those trial sites were well short of reaching intended recruitment targets.
A study at the government-run AIIMS medical institute had only signed up some 200 participants, compared with a goal of 1,500-2,000, Reuters partner ANI reported last week, citing a doctor at the institute.
The shot, called COVAXIN, was evaluated in about 1,000 participants in early and mid-stage trials.
“We are overwhelmed with the steady rise in participation,” Bharat Biotech joint MD Suchitra Ella said in a statement on Tuesday.
With more than 10 million infections, India, the world's biggest vaccine producing country, is also the second worst-hit nation by Covid-19 behind the US, though the rate of growth in infections has been slowing.
Its drug regulators are in talks with US firms Pfizer and Moderna — whose Covid-19 vaccines have been approved in the US — while other vaccine candidates including AstraZeneca's shot are in trials.
Would you like to comment on this article or view other readers' comments? Register (it’s quick and free) or sign in now.
Please read our Comment Policy before commenting.